Dr. Dorff on Second-line Immune Checkpoint Inhibitors in Metastatic RCC

Tanya Dorff, MD, medical oncologist, associate clinical professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma (RCC).

The role of immune checkpoint inhibitors in the second-line setting is unclear for patients with metastatic RCC who were exposed to an immune checkpoint inhibitor in the first-line setting, Dorff says. The current frontline standard of care for metastatic RCC includes immuno-oncology (IO) plus VEGF TKI or IO plus IO combinations, and many patients experience prior exposure to immune checkpoint inhibitors when they reach the second line.

Ongoing trials aim to address this need, and these results could help better inform second-line treatment decisions for patients with metastatic RCC who were previously treated with animmune checkpoint inhibitor, Dorff concludes.